Ganciclovir is a nucleoside analog structurally related to Acyclovir that acts as a prodrug activated by phosphorylation. Ganciclovir has been used in the study of "suicide" gene therapy in cancer research, where upon expression of a viral suicide gene encoding herpes simplex virus, thymidine kinase (TK), the non-toxic prodrug ganciclovir, is converted to an active phosphorylated analog that can be incorporated into the DNA of replicating eukaryotic cells, causing death of the malignant dividing cell. Causes an irreversible cell cycle arrest at the G2/M checkpoint. Ganciclovir has also been used to study the loss of telomeres and to evaluate sensitivity of viruses to antiviral agents.
Aghi, M., et al. 2000. J. Gene Med. 2, 148. Qiao, J., et al. 2000. Hum. Gene Ther. 11, 1569. Cannon, J.S., et al. 1999. J. Virol. 73, 4786. Rubsam, L.Z., et al. 1999. Cancer Res. 59, 669. Sprung, C.N., et al. 1999. Proc. Natl. Acad. Sci. USA 96, 6781. Yamasaki, H., et al. 1999. C.R. Acad. Sci. III 322, 151. Halloran, P.J., and Fenton, R.G. 1998. Cancer Res. 58, 3855.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.